PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
Conditions: NK-T-Cell Lymphoma, Extranodal Interventions: Drug: 4 cycles of ESA regimen with sandwiched radiotherapy; Drug: 2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase; Drug: 2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase Sponsors: Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023
Fast Track designation can potentially accelerate KT-333’s development... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 18, 2023 Category: Pharmaceuticals Source Type: clinical trials
Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study
Condition: Cutaneous T-cell Lymphoma Intervention: Drug: Linperlisib in combined with Chidamide Sponsor: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2023 Category: Research Source Type: clinical trials
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan
Condition: Relapsed or Refractory T-cell Lymphomas Intervention: Drug: BMS-986369 Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
